Market OpportunityCreto's potential to tap into BCG-naïve in high-risk and intermediate-risk populations is not yet fully reflected in the stock, suggesting expansion opportunities could propel Creto as a key option for NMIBC.
Regulatory ApprovalCreto is well set on its path to file its first BLA with potential approval expected, demonstrating a strong profile in BCG-unresponsive, high-risk NMIBC.
Safety And EfficacyCreto demonstrated a pristine safety profile with no treatment-related Grade ≥3 adverse events reported.